Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

医学 聚乙二醇干扰素 乙型肝炎表面抗原 内科学 HBeAg 胃肠病学 养生 乙型肝炎 乙型肝炎病毒 α-干扰素 α-干扰素 免疫学 干扰素 慢性肝炎 病毒 利巴韦林
作者
Marc Bourlière,Pascaline Rabiéga,Nathalie Ganne‐Carrié,Lawrence Serfaty,Patrick Marcellin,Yoann Barthe,Dominique Thabut,Dominique Guyader,Christophe Hézode,Magali Picon,Xavier Causse,Vincent Leroy,J.-P. Bronowicki,Patrizia Carrieri,Ghassan Riachi,Isabelle Rosa,P Attali,Jean‐Michel Molina,Yannick Bacq,Albert Tran,Jean Didier Grangè,Fabien Zoulim,Hélène Fontaine,Laurent Alric,Inga Bertucci,Magali Bouvier–Alias,Fabrice Carrat
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:2 (3): 177-188 被引量:90
标识
DOI:10.1016/s2468-1253(16)30189-3
摘要

Background Findings from uncontrolled studies suggest that addition of pegylated interferon in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos(t)ide analogues with undetectable plasma hepatitis B virus (HBV) DNA might increase HBs antigen (HBsAg) clearance. We aimed to assess this strategy. Methods In this randomised, controlled, open-label trial, we enrolled patients aged 18–75 years with HBeAg-negative chronic hepatitis B and documented negative HBV DNA while on stable nucleos(t)ide analogue regimens for at least 1 year from 30 hepatology tertiary care wards in France. Patients had to have an alanine aminotransferase concentration of less than or equal to five times the upper normal range, no hepatocellular carcinoma, and a serum α fetoprotein concentration of less than 50 ng/mL, normal dilated fundus oculi examination, and a negative pregnancy test in women. Patients with contraindications to pegylated interferon were not eligible. A centralised randomisation used computer-generated lists of random permuted blocks of four with stratification by HBsAg titres (< or ≥2·25 log10 IU/mL) to allocate patients (1:1) to receive a 48 week course of subcutaneous injections of 180 μg per week of pegylated interferon alfa-2a in addition to the nucleos(t)ide analogue regimen or to continue to receive nucleos(t)ide analogues only. The primary endpoint was HBsAg loss at week 96 by intention-to-treat analysis. This trial is closed and registered with ClinicalTrials.gov, number NCT01172392. Findings Between Jan 20, 2011, and July 18, 2012, we randomly allocated 185 patients (92 [50%] to pegylated interferon and nucleos(t)ide analogues and 93 [50%] to nucleos(t)ide analogues alone). We excluded two patients from the pegylated interferon plus nucleos(t)ide analogues group from analyses because of withdrawal of consent (one patient) or violation of inclusion criteria (one patient). At week 96, loss of HBsAg was reported in seven (7·8%) of 90 patients in the pegylated interferon plus nucleos(t)ide analogues group versus three (3·2%) of 93 in the nucleos(t)ide analogues-alone group (difference 4·6% [95% CI −2·6 to 12·5]; p=0·15). 85 (94%) of 90 patients started pegylated interferon, three (4%) of whom had a dose reduction and 17 (20%) had an early discontinuation of pegylated interferon (seven [41%] for serious adverse events). Grade 3 and 4 adverse events were more frequent in the pegylated interferon plus nucleos(t)ide analogues group (26 [29%] grade 3 adverse events; 19 [21%] grade 4 adverse events) than in the nucleos(t)ide analogues-alone group (three [3%] grade 3; six [6%] grade 4). Interpretation Addition of a 48 week course of pegylated interferon to nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B with undetectable HBV DNA for a least 1 year was poorly tolerated and did not result in a significant increase of HBsAg clearance. Funding Institut national de la santé et de la recherche médicale-Agence nationale de recherches sur le sida et les hépatites virales (France Recherche Nord&sud Sida-vih Hepatites).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助lvsehx采纳,获得10
刚刚
刚刚
duolaAmeng完成签到,获得积分10
刚刚
Jiang完成签到,获得积分10
1秒前
向上的小v完成签到 ,获得积分10
1秒前
Tammy完成签到,获得积分10
1秒前
最最完成签到,获得积分10
2秒前
lee完成签到 ,获得积分10
2秒前
大力黑米完成签到 ,获得积分10
2秒前
蔡俊辉发布了新的文献求助10
3秒前
bastien完成签到 ,获得积分10
3秒前
共享精神应助ZLS采纳,获得10
3秒前
ProfWang应助你比我笨采纳,获得10
4秒前
ggg发布了新的文献求助10
4秒前
liangliu完成签到,获得积分10
5秒前
飞翔的霸天哥应助Jane采纳,获得30
5秒前
纯洁完成签到,获得积分10
5秒前
6秒前
Fei发布了新的文献求助10
6秒前
文文完成签到,获得积分10
8秒前
8秒前
科研通AI2S应助camille采纳,获得10
9秒前
Accepted应助oneinlove采纳,获得10
9秒前
Cloud应助coco采纳,获得10
9秒前
9秒前
俊逸绮烟完成签到,获得积分10
10秒前
易拉罐完成签到,获得积分10
10秒前
10秒前
10秒前
萌~Lucky完成签到,获得积分10
10秒前
10秒前
蔡俊辉完成签到,获得积分10
11秒前
小蘑菇应助Tangerine采纳,获得10
11秒前
搜集达人应助搬砖美少女采纳,获得10
12秒前
wt发布了新的文献求助10
13秒前
will完成签到 ,获得积分10
13秒前
晓风拂楠完成签到,获得积分10
13秒前
龙龙完成签到 ,获得积分10
13秒前
淡淡从阳完成签到,获得积分10
13秒前
周少完成签到,获得积分10
14秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099914
求助须知:如何正确求助?哪些是违规求助? 2751373
关于积分的说明 7613446
捐赠科研通 2403368
什么是DOI,文献DOI怎么找? 1275253
科研通“疑难数据库(出版商)”最低求助积分说明 616318
版权声明 599053